AVCR Avricore Health

Avricore Health Completes $1.5 Million Financing

Avricore Health Completes $1.5 Million Financing

VANCOUVER, British Columbia, Jan. 26, 2021 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) announces it has closed the final tranche of its non-brokered private placement for gross proceeds of $874,000 to complete its $1.5 million financing. The Company will issue 8,740,000 units at $0.10 per unit and will pay finders fees totaling $29,050 and issue 290,500 finders warrants. Insiders participated in the aggregate amount of $88,000 for 880,000 units. Placement proceeds will be used for general working capital purposes.  

“We are honoured to have had this level of support in challenging times.”  Said Hector Bremner, CEO of Avricore Health. “It demonstrates the strong sentiment and belief in our mission, and our team. We look forward to now delivering on our work and expanding HealthTab™ to more pharmacies and other applications."

Each Unit consists of one common share and one transferrable share purchase warrant. Each warrant will entitle the holder thereof to purchase one additional common share for a period of 12 months from the closing date of the offering at a price of $0.15 per common share provided that if the closing price of the common shares of the Company on any stock exchange or quotation system on which the common shares are then listed or quoted is equal to or greater than $0.20 for a period of fifteen (15) consecutive trading days, the Company will have the right to accelerate the expiry of the warrants to a date that is not less than ten (10) business days from the date notice is given.

Closing of the Private Placement is subject to final acceptance by the TSX Venture Exchange. All securities issued in connection with the Private Placement will be subject to a four-month hold period from the closing date under applicable Canadian securities laws.

The Private Placement securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "1933 Act"), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.

Contact:

Hector Bremner, CEO 604-773-8943

 

 

About Avricore Health Inc.

Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company's goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



EN
26/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avricore Health

 PRESS RELEASE

Avricore Health’s HealthTab™ Platform Expands to North Central London ...

Avricore Health’s HealthTab™ Platform Expands to North Central London in Groundbreaking NHS Pharmacy-Led Cardiovascular Project VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) is pleased to announce the expansion of its HealthTab™ platform into pharmacies in North Central London—making it the second NHS Integrated Care Board (ICB), after North East London, to join this groundbreaking initiative aimed at tackling health inequalities through cholesterol screening. Six (6) new HealthTab™ systems were deployed in t...

 PRESS RELEASE

Avricore Grants Options

Avricore Grants Options VANCOUVER, British Columbia, June 14, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) today announces that the Company’s board of directors has approved the granting of stock options (the “Options”) exercisable for a total of 4,100,000 common shares to its directors, officers, employees and consultants at an exercise price of CAD $0.05 per common share. All Options were granted pursuant to the Company’s stock option plan and are subject to the terms of the applicable grant agreements and the requirements of the TSX Ventur...

 PRESS RELEASE

Avricore Appoints Rodger Seccombe as CEO

Avricore Appoints Rodger Seccombe as CEO VANCOUVER, British Columbia, June 05, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) is pleased to report the appointment of Rodger Seccombe as CEO of the Company. Mr. Seccombe currently serves as Chief Technology Officer of Avricore and is the President and Co-Founder of its wholly owned subsidiary, HealthTab™ Inc. David Hall, Chairman of the board stated, “In his role as Avricore’s CTO Rodger has been instrumental in the development of the Company’s flagship HealthTab platform. We are excited to have Rod...

 PRESS RELEASE

AVRICORE HEALTH CORPORATE UPDATE: Q1 Results and Ongoing Progress Repo...

AVRICORE HEALTH CORPORATE UPDATE: Q1 Results and Ongoing Progress Report VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) reports on its result for the first quarter of 2025 and its progress towards expansion objectives for the balance of the year. For the three months ended March 31, 2025 the Company realized revenues of $434,061 with a gross profit of $346,297. The Company recorded a comprehensive loss of $77,300 with a net increase in cash of $137,068. Plan the Work – Work the Plan The Company is currently...

 PRESS RELEASE

AVRICORE HEALTH CORPORATE UPDATE: 2024 record year, UK expansion on tr...

AVRICORE HEALTH CORPORATE UPDATE: 2024 record year, UK expansion on track VANCOUVER, British Columbia, May 01, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) reports on its year end 2024 and In the year ended December 31, 2024 revenue increased by 37% year over year to $4,785,711 and gross profit increased by 56% to $1,880,306.In the three months ended December 31, 2024 revenue increased by 5% year over year to $1,421,076 and gross profit increased by 18% to $589,930. “Launching and expanding HealthTab™ in North East ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch